Milestone Pharmaceuticals Prices Public Offering to Fuel Advancement of Innovative Cardiovascular Medicines

Milestone Pharmaceuticals Announces Pricing of Public Offering to Advance Innovative Cardiovascular Medicines
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 - Milestone Pharmaceuticals Inc. (Milestone) (Nasdaq: MIST), a biopharmaceutical company specializing in the development and commercialization of groundbreaking cardiovascular medications, has recently declared the pricing of its underwritten public offering. The offering consists of 16,666,667 common shares at a public offering price of $1.50 per share, as well as pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant. This move is expected to generate approximately $30.0 million in proceeds for Milestone, of which the underwriters have an option to purchase an additional 3,000,000 common shares. The financing is anticipated to close on or around March 4, 2024, contingent upon fulfilling customary closing conditions.
Milestone Pharmaceuticals is a renowned establishment dedicated to addressing the unmet needs within the cardiovascular treatment landscape. This recent public offering will provide the company with additional funds to advance its pipeline of innovative cardiovascular medicines. With an emphasis on developing groundbreaking therapies, Milestone aims to improve patient care and revolutionize the treatment options available for cardiovascular diseases.